Jehl F, Quoix E, Leveque D, Pauli G, Breillout F, Krikorian A, Monteil H
Department of Pharmacokinetics, Institute of Bacteriology, Paris, France.
Cancer Res. 1991 Apr 15;51(8):2073-6.
The pharmacokinetics and metabolism of Navelbine (NVB) were investigated in 20 patients by a specific high performance liquid chromatographic methodology allowing the monitoring of NVB, deacetyl-NVB, and N-oxide NVB. After the i.v. (15 min) administration of 30 mg/m2 of drug, blood and urine samples were collected for, respectively, 144 and 48 h. NVB is characterized by a three compartmental kinetics, with a Cmax of 1130 +/- 139 (SEM) ng/ml. The total body clearance and apparent volume of distribution, as defined by high performance liquid chromatography, are 1.26 +/- 0.09 liter/h/kg (48.6 +/- 4.1 liters/h/m2) and 75.6 +/- 9.2 liters/kg (2918.4 +/- 307.2 liters/m2). No metabolite could be detected in serum; the urinary excretion of NVB represented 11% of the administered dose. Deacetyl-NVB could be identified as a minor urinary metabolite when no N-oxide NVB appeared in the urine samples. Two additional peaks appeared in most of urinary chromatograms as trace amounts. Thus, the major pathway of NVB, as for other Vinca alkaloids, should be hepatic clearance, as biliary elimination and/or hepatic biotransformation.
采用一种能监测诺维本(NVB)、去乙酰诺维本及N-氧化诺维本的高效液相色谱法,对20例患者的诺维本药代动力学及代谢情况进行了研究。静脉注射(15分钟)30mg/m²药物后,分别在144小时和48小时采集血样和尿样。诺维本具有三室动力学特征,Cmax为1130±139(SEM)ng/ml。通过高效液相色谱法测定的总体清除率和表观分布容积分别为1.26±0.09升/小时/千克(48.6±4.1升/小时/平方米)和75.6±9.2升/千克(2918.4±307.2升/平方米)。血清中未检测到代谢物;诺维本的尿排泄量占给药剂量的11%。当尿样中未出现N-氧化诺维本时,去乙酰诺维本可被鉴定为一种次要的尿代谢物。在大多数尿色谱图中还出现了两个微量的额外峰。因此,与其他长春花生物碱一样,诺维本的主要代谢途径应为肝脏清除,包括胆汁排泄和/或肝脏生物转化。